Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01BAU
|
|||
| Former ID |
DNCL003079
|
|||
| Drug Name |
SPN-812
|
|||
| Indication | Attention deficit hyperactivity disorder [ICD-11: 6A05.Z; ICD-9: 314] | Phase 2 | [1] | |
| Company |
Supernus Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Norepinephrine transporter (NET) | Target Info | Inhibitor | [2] |
| Panther Pathway | Adrenaline and noradrenaline biosynthesis | |||
| Reactome | Na+/Cl- dependent neurotransmitter transporters | |||
| WikiPathways | Monoamine Transport | |||
| NRF2 pathway | ||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01107496) A Phase I/IIa, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study of the Safety, and Efficacy of SPN-812V in Adults With Attention Deficit Hyperactivity Disorder (ADHD). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.